Phase I/II Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 22 Oct 2012
At a glance
- Drugs Pidilizumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 27 Sep 2011 Planned end date changed from 1 Oct 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 27 Sep 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.